|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.08.25 - 14:09
|
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
|
|
|
-- Reached Alignment with the U.S. Food and Drug Administration (FDA) on Information Needed for Resubmission of the Biologics License Application (BLA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) --
-- Plan to Resubmit the BLA in December with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Will Request Priority Review --
-- Anticipate Submitting the MOLBREEVI Marketing Authorization Applications for Autoimmune PAP to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 1Q 2026 --
-- Reported ~$146M in Cash and Short-Term Investments as of June 30, 2025, Company Believes It Is Sufficiently Capitalized into 1Q 2027 --LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2025 and provided a business update.
“Fo...
|
|
|
|
|
|
|
12.08.25 - 00:51
|
Zoetis Announces Pricing of $1.85 Billion of Senior Notes (Business Wire)
|
|
|
PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering.
Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.400% senior notes due 2025 in the aggregate principal amount of $600 million, and (iii) the remainder for general corporate purposes. The offering is expected to close on August 18, 2025, subject to customary closing conditions.
Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when availa...
|
|
|
11.08.25 - 23:01
|
US Extends China Truce, Open to Scaled-Back Blackwell Sales | Bloomberg Businessweek Daily 8/11/2025 (Bloomberg)
|
|
|
On today's episode of Bloomberg Businessweek Daily, Tim Stenovec and Isabelle Lee speak with Jordan Klein, Managing Director at Mizuho Securities USA on the signal from President Trump that he would be open to allowing Nvidia Corp. to sell a scaled-back version of its most advanced AI chip to China. They also spoke with Senior Non-Resident Fellow at New York University Ed Price on Trump's extension of the 90 day trade truce with China, and upcoming summit with Russian President Vladimir Putin. Finally, Tim Herbert, president and CEO of Inspire Medical System, discussed his company's earnings and share buyback announcement. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
